重组水蛭素的表达和纯化及临床应用进展
作者：陈素芹;欧瑜;
Author：
收稿日期： 年卷（期）页码：2010,25(06):-756-758
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：重组水蛭素;表达;纯化;临床应用
Key words：
基金项目：
中文摘要
重组水蛭素为基因工程的产物,与天然水蛭素有相同的功效,为新一代高效安全的抗凝、防栓药物。文中综述了重组水蛭素的表达、纯化及临床应用的研究。
参考文献
[1]李超,张相年,石磊.水蛭素及其临床应用[J].实用医学杂志,2007,23(21):3458-3459.
[2]De Taxis du Poet P,Scacheri E,Benatti L,et al.Production ofthe HV1 variant of hirudin by recombinant DNA methodology[J].Blood Coagul Fibri nolysis,1991,2:113-120.
[3]郭娟,王荷碧,顾洁,等.重组水蛭素克隆的表达及其产物的分离纯化[J].中华血液学杂志,1998,19(3):146-148.
[4]谭树华,吴梧桐,刘景晶.水蛭素3(HV3)基因的合成、克隆与鉴定[J].药物生物技术,1998,5(1):1-5.
[5]杨宇峰,周建,耿旭,等.水蛭素-RGD序列融合蛋白基因在枯草芽孢杆菌中的克隆及表达[J].华东师范大学学报,2005,11(4):102-105.
[6]Loison G,Courtney M,Lemoine Y,et al.Production and evalua-tion of recombinant hirudin[J].Semin Thromb Hemost,1989,15:288-292.
[7]Yang J,Zhou X,Zhang Y.Improvement of recombinant hirudinproduction by controlling NH4+concentration in Pichia pastorisfermentation[J].Biotechnol Lett,2004,26:1013-1017.
[8]Chaudhary S,Parmenter DL,Moloney MM.Transgenic Brassicacarinata as a vehicle for the production of recombinant proteins inseeds[J].Plant cell rep,1998,17:195-200.
[9]Sun YL,Chou YC,Kuan TC,et al.Expression of recombinantanticoagulant hirudin in the differentiated cultures of the porcinemammary epithelial cell line SI-PMEC[J].Cell Biology Inter,2008,32:739-747.
[10]Chung BH,Sohn JH,Rhee SK.Enhanced metal affinity partitio-ning of genetically engineered hirudin variants in polyethyleneglycolPdextran two-phase systems[J].Ferment Bioeng,1994,77:75-79.
[11]昝云红,孙茂盛,李智华,等.啤酒酵母生产的重组水蛭素的纯化及脱色[J].中国生物化学与分子生物学报,1999,15(5):779-781.
[12]周卫斌,周祥山,张元兴.毕赤酵母发酵液的脱色和重组水蛭素的分离[J].生物工程学报,2001,17(6):683-687.
[13]邵雷,周长林,范维,等.发酵液中重组水蛭素的分离纯化[J].中国药科大学学报,2003,34:268-271.
[14]崔莉,谭树华,章良,等.重组水蛭素Ⅲ的分离纯化与鉴定[J].中国药科大学学报,2005,36(1):78-81.
[15]陈华友,齐向辉,耿旭,等.枯草杆菌重组水蛭素的分离纯化工艺研究[J].安徽农业科学,2009,37(34):16757-16759,16768.
[16]Topol EJ,Fuster V,Harrington RA,et al.Recombinant hirudin forunstable angina pectoris:A multicenter randomized angiographictrial[J].Circulation,1994,89:1557-1566.
[17]Moustapha A,Anderson HV.Contemporary viewof the acute cor-onary syndromes[J].J Invasive Cardiol,2003,15(2):71-79.
[18]Eriksson BI.Newtherapeutic options in deep vein thrombosisprophylaxis[J].Semin Hematol,2000,37(3 Suppl 5):7-9.
[19]Warkentin TE.Management of heparin-induced thrombocytope-nia:a critical comparison of lepirudin and argatroban[J].Thromb Res,2003,110(2/3):73-82.
[20]Lubenow N,Greinacher A.Hirudin in heparin-induced throm-bocytopenia[J].Semin Thromb Hemost,2002,28(5):431-438.
[21]Schiele F,Vuillemenot A,Kramarz P,et al.Use of recombinanthirudin as antithrombotic treatment in patients with heparin-in-duced thrombocytopenia[J].Am J Hematol,1995,50(1):20-55.
[22]Petros S.Lepirudin in the management of patients with heparin-induced thrombocytopenia[J].Biologics,2008,2(3):481-490.
[23]莫炜,宋后燕.重组水蛭素临床应用的研究进展[J].国外医学药学分册,2004,31(2):82-86.
[24]Nutescu EA,Shapiro NL,Chevalier A,et al.New AnticoagulantAgents:Direct Thrombin Inhibitors[J].Cardiology Clinics,2008,26(2):169-187.
[25]Warkentin TE.Bivalent direct thrombin inhibitors:hirudin andbivalirudin[J],Best Pract Res Clin Haematol,2004,17:105-125.
【关闭】
